Long before she became a pioneering scientist, Professor Liesl Zühlke insisted on seeing her tonsils after they were removed when she was just five years old. Today, paediatric cardiology is close to her heart, and her research has helped answer critical questions in the entire pipeline of heart disease.
A high-profile court case has thrust the legalities of compounding medicines in South Africa into the spotlight. Behind the immediate legal issues, hide a series of unresolved questions about how we should ensure that compounded medicines used in South Africa are safe, argue Professor Renier Coetzee and Lara van Niekerk.
In part 3 of a Spotlight special series on the role of new weight loss medicines like Ozempic in South Africa, we ask what these breakthrough jabs might mean for people living with HIV in the country. There is some tantalising early research on potential benefits, but also many uncertainties. Catherine Tomlinson reports.
Universal health coverage cannot succeed with fragmented systems, weak data, and largely symbolic participation. A recent court-ordered pause to NHI implementation offers a chance to build the foundations properly, argue Dr Haseena Majid and Professor Mogie Subban.
Funding cuts over the last year or so have created a crisis for multilateral health institutions. Which institutions emerge from this crisis, and in what form, will have real consequences for the health of people in South Africa, argues Spotlight editor Marcus Low.
In South Africa, access to weight loss medicines like Ozempic and Mounjaro remains limited to those who can shell out a few thousand Rand a month. In the second article of a Spotlight special series, Catherine Tomlinson looks at the medical need for these medicines in the country and what it would take for government to provide them in the public sector.
District managers in South Africa’s public healthcare system currently have to juggle funding from multiple government budget lines, each with different strings attached. To improve district health services, we urgently need to simplify and integrate these funding flows, argues Russell Rensburg.
Sales of weight loss medicines like Ozempic and Mounjaro have sky-rocketed in South Africa in recent years, although they remain too expensive for most people who might benefit from the jabs. In the first article of this Spotlight special series, Catherine Tomlinson tracks their remarkable rise and assesses when they will become more widely available here.
Getting to grips with rising diabetes rates is arguably one of the most urgent tasks for South Africa’s public healthcare system, but the setbacks keep coming. While some communities are facing shortages of blood sugar meters and insulin pens, a smaller wave of insulin vial shortages is now on the horizon, reports Joan van Dyk.
The remarkable efficacy of new diabetes and weight loss medicines like Ozempic and Mounjaro have been one of the biggest health stories of recent years. Despite rising rates of diabetes and obesity, access to these medicines remain limited in South Africa. Catherine Tomlinson asks which of the GLP-1 agonists are available here and at what price.
With South Africa’s healthcare system facing a myriad challenges, experts at a health conference have put forward a range of practical solutions to address some of the country’s pressing issues. Ufrieda Ho rounds up some of the proposed solutions to improve patient care, including the use of public-private partnerships.
The South African government has adopted a national target to bring the blood sugar levels of people with diabetes under control. But beyond the target, the country’s response to diabetes is falling far short. In this Spotlight special briefing, Catherine Tomlinson looks at what the country needs to do to better manage this often fatal disease and how we can draw lessons from the response to HIV.
